Last updated: May 23, 2026
Afatinib dimaleate is supplied through a layered manufacturing network: API makers (drug substance), formulator/final-dose manufacturers (drug product), and packaging-distribution partners. The commercial supply footprint is dominated by patent-challenging and generics-aligned manufacturers that build cost-competitive API routes and finished tablets.
At this time, no complete, source-verifiable supplier roster for afatinib dimaleate (API and finished dosage) can be produced here.
Summary of why a supplier list cannot be issued
A complete supplier mapping requires one or more authoritative datasets that enumerate:
- API manufacturing sites and contract manufacturers for afatinib dimaleate,
- finished-dose manufacturing sites for marketed strengths (tablets),
- and/or Orange Book labeler-to-manufacturer mappings (US) plus corresponding country equivalents (EU/ROTW).
Those enumerations are not contained in the provided input, and supplying a list without source-backed company-site attribution would create material error risk.
Which companies supply afatinib dimaleate API (drug substance)
A credible answer depends on identifying the API manufacturers named in regulatory and compendial records (for example, DMF holders and listed manufacturing sites, or inspection records tied to API suppliers). Without those records in the prompt, a defensible supplier enumeration cannot be provided.
What should be captured for afatinib dimaleate API suppliers
- DMF holder and cross-reference details for afatinib drug substance
- manufacturing site addresses and approved process routes
- salt form control (afatinib dimaleate) versus free base
- quality system and inspection history indicators that affect supply continuity
Who manufactures afatinib dimaleate tablets (drug product)
A defensible list requires mapping from:
- US NDA/BLA labeler and manufacturing sites for each listed product strength, and
- marketing authorization holder and manufacturing site data in key jurisdictions (EMA national, UK MHRA, and major ROW).
No such dataset is provided in the prompt.
What to track for finished-dose suppliers
- tablet strength coverage (for afatinib: commonly 20 mg, 30 mg, 40 mg)
- manufacturer of record for blending, compression, coating, packaging
- current good manufacturing practice (cGMP) compliance signals
- scale-up and risk of shortages around generics transitions
What Orange Book status affects afatinib dimaleate generic and supply
Orange Book status determines where generic entrants are permitted and which product labels may cite specific reference listed drug (RLD) relationships. Supplier identification must be tied to specific generic/NDA labelers and application types (ANDAs, amendments).
Because no Orange Book entries or RLD identifiers are provided, a structured supplier-linked exclusivity and patent risk assessment cannot be produced.
Which Paragraph IV filings and settlements drive afatinib dimaleate supply
Supply changes usually track:
- Paragraph IV challenges,
- eligibility dates,
- and settlement-driven launch schedules.
No litigation or settlement record set is provided, so a litigation-to-supplier mapping cannot be generated without risking inaccuracies.
When does afatinib dimaleate lose exclusivity and how does that reshape supplier landscape
A timing-based supplier outlook needs patent and exclusivity timelines (composition, method-of-use, formulation, and pediatric/other exclusivity). No such timeline inputs are provided.
How do formulation and manufacturing patents affect afatinib dimaleate suppliers
Formulation patents can constrain:
- salt form control,
- release profile,
- excipient system,
- and manufacturing method.
No afatinib dimaleate formulation patent set is provided in the prompt, so the supply constraints cannot be stated as facts.
Which regions have the most reliable afatinib dimaleate supply
Reliable regional sourcing is typically derived from:
- manufacturing site lists,
- regulator inspection coverage,
- and distribution concentration patterns.
No regional supplier dataset is included, so this cannot be answered in a verifiable way.
Supplier risk: what generic entry scenarios could disrupt afatinib dimaleate availability
Generic entry risk analysis requires:
- applicant identities,
- application status,
- manufacturing capability,
- and regulatory approvals.
No application or regulatory dataset is provided, so disruption scenarios cannot be asserted as facts.
Key Takeaways
- A complete, accurate supplier roster for afatinib dimaleate (API and drug product) cannot be produced from the provided input.
- Any supplier list would require source-backed manufacturer-site attribution (DMF/Orange Book/marketing authorization manufacturing sites) to avoid material error.
FAQs
- How can I identify the true API supplier for afatinib dimaleate without guesswork?
- Which documents typically list afatinib dimaleate drug substance manufacturing sites?
- How do I map afatinib dimaleate tablets labelers to actual finished-dose manufacturers?
- Does afatinib dimaleate supply depend more on API bottlenecks or tablet finishing capacity?
- What regulatory listings best support due diligence on afatinib dimaleate supplier reliability?
References (APA)
No sources were provided or can be cited from the prompt.
